Anti-EGFR antibodies are used for the treatment of RAS wild type metastatic colorectal cancer. We previously showed that EGFR gene copy number (GCN) predicts response to anti-EGFR therapy in KRAS exon 2 wild type metastatic colorectal cancer. The aim of our study was to analyse the predictive role of EGFR GCN in RAS/BRAF/PIK3CA wild type metastatic colorectal cancer. The material included 102 patients with KRAS exon 2 wild type metastatic colorectal cancer treated with anti-EGFR 6 cytotoxic therapy. Next generation sequencing was used for KRAS, NRAS, BRAF and PIK3CA gene mutation analyses. EGFR GCN was analysed by EGFR immunohistochemistry guided automated silver in situ hybridisation. Increased EGFR GCN (4.0) predicted a better response and prolonged progression free survival in anti-EGFR treated RAS/BRAF/PIK3CA wild type patients (Log-rank test, p 5 0.0004). In contrast, survival of RAS/BRAF/PIK3CA wild type, EGFR GCN below 4.0 patients did not differ from patients with mutant RAS, BRAF or PIK3CA. Our study indicates that EGFR GCN predicts anti-EGFR treatment efficacy in patients with RAS/BRAF/PIK3CA wt metastatic CRC. Tumours with EGFR GCN below 4.0 appear to be as refractory to anti-EGFR treatment as tumours with mutation in any of the RAS/RAF/PIK3CA pathway genes.
Introduction
Anti-EGFR monoclonal antibodies cetuximab and panitumumab were introduced in the treatment arsenal of metastatic colorectal cancer (CRC) about 10 years ago and at first used in an unselected patient population. Subsequent studies identified KRAS exon 2 gene mutations in codons 12 and 13 as a negative predictive marker for anti-EGFR treatment response and the treatment option was therefore restricted to only KRAS exon 2 wild-type (wt) metastatic CRC patients. 1, 2 More recently, the patient population expected to benefit from anti-EGFR therapy has been further defined to include only those without mutations in the KRAS (exons 3 and 4 in addition to exon 2) and NRAS (exons 2-4) genes, e.g. the so called RAS wild-type patients. 3, 4 Despite the undisputable prognostic role of activating BRAF mutations in metastatic CRC, the predictive role of BRAF mutations has remained unclear. However, a recent meta-analysis concludes that the addition of cetuximab or panitumumab to cytotoxic therapy does not benefit patients with BRAF mutated tumours in terms of progression free survival (PFS), overall survival (OS) or ORR (overall response rate). 5 The predictive role of activating mutations in PIK3CA belonging to the PI3K-PTEN-AKT signalling pathway downstream of EGFR have also been studied in KRAS and RAS wt metastatic CRC patients treated with anti-EGFR monoclonal antibodies. The results have been inconclusive, but suggest that PIK3CA mutations, particularly those in exon 20, are negative predictors for anti-EGFR treatment efficacy. [6] [7] [8] While the new markers are useful in stratifying metastatic CRC patients benefitting from anti-EGFR treatment, a significant fraction of the selected patients do not show objective response. 9 We previously showed that a high EGFR GCN (4.0), as analysed by a technique, which combines immunohistochemistry and in situ hybridisation is associated with improved anti-EGFR treatment response, prolonged OS and PFS in metastatic or locally advanced KRAS exon 2 wt CRC. 10, 11 To extend the understanding of factors regulating anti-EGFR therapy, we here combined EGFR GCN analysis with next generation sequencing (NGS) of the RAS/BRAF/PI3KCA genes in a cohort of 102 metastatic CRC patients. The molecular subgroups were evaluated for treatment response, PFS and OS.
Materials and Methods

Patients
The study cohort included 75 previously characterised KRAS exon 2 wt metastatic CRC patients. 10, 11 In addition, we included 27 new patients with metastatic CRC treated with anti-EGFR therapy 6 cytotoxic therapy at the Turku University Hospital (2010-2013) for whom both EGFR GCN analysis and expanded RAS gene testing results were available. The majority of the patients received anti-EGFR therapy in combination with irinotecan 6 5-FU. About 30% of the patients were treated with single panitumumab or cetuximab. The median follow-up time of all patients included in our study calculated from the onset of anti-EGFR 6 cytotoxic therapy was 12.1 months (range 1.5-58.5 months). Characteristics of the 88 patients, from whom all relevant information was available, are shown in Table 1 .
The anti-EGFR treatment response was evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 12 by using either computed tomography (CT), magnetic resonance imaging (MRI) or positron emission tomography-CT (PET-CT).
Ethics statement
The study was conducted in accordance with the declaration of Helsinki. The histological samples were collected and analysed and the clinical data retrieved with the endorsement of the National Authority for Medico-Legal Affairs, the Institutional Review Board of the Hospital District of Southwest Finland and Ethical Review Board at Helsinki University Hospital. Oral or written informed consent was not obtained due to the fact that the majority of the patients included in our study had died of their disease. The need for informed consent from participants was waived by the National Authority for Medico-Legal Affairs.
RAS, PIK3CA, BRAF mutation analysis, IHC and SISH procedures
Initially KRAS point mutations within codons 12 and 13 were detected from formalin-fixed paraffin-embedded samples with at least 30% of CRC cells by using the DxS K-RAS mutation kit (DxS Ltd, Manchester, UK). Additional gene mutation analysis was performed by using the NGS method. DNA was extracted from FFPE samples after deparaffinization using a MaxwellV R 4 .0 (Life Technologies, Carlsbad, CA, USA). After trimming and alignment to the hg19 human reference genome, sequence variants were detected using the VariantCaller v4.0 (Life Technologies, Carlsbad, CA, USA). The Ion Reporter software v4.0 (Life Technologies, Carlsbad, CA, USA) was used to filter out non-coding and polymorphic variants. All variants listed after filtering were visualised in the Integrative Genomics Viewer (IGV) to discard manually alterations generated by incorrect calling.
What's new?
Monoclonal antibodies targeting the epidermal growth factor receptor (EGFR) are an important therapeutic option for patients with RAS wild-type metastatic colorectal cancer. However, the efficacy of anti-EGFR therapy may be undermined by the presence of mutations in other EGFR pathway genes. According to this study, in order to better predict anti-EGFR therapeutic response, the addition of EGFR gene copy number (GCN) analysis to the biomarker panel used today seems to be a promising approach. EGFR GCN of 4.0 predicted positive response and favourable survival in anti-EGFR-treated RAS/BRAF/PIK3CA wildtype patients. No survival benefits were detected, however, when EGFR GCN was below 4.0.
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Detailed methods for EGFR immunohistochemistry (IHC)
and EGFR GCN analysis have been described. 10 In brief, three mm sections were stained with EGFR (clone 5B7) mAb (Ventana Medical Systems/Roche Diagnostics, Tucson, AZ). Stainings were performed with BenchMark XT (Ventana/ Roche) using ultraVIEW Universal DAB Detection Kit (Ventana/Roche). EGFR gene was detected from subsequent five lm sections with EGFR DNA Probe (Ventana/Roche) and ultraVIEW silver in situ hybridisation (SISH) Detection Kit (Ventana/Roche). EGFR GCN of forty tumour cells was analysed using a 40x objective by two observers (ML, JS) from areas of highest IHC reactivity in each tumour. The cut-off used for EGFR GCN 4.0 was based on previously performed ROC analysis. 10 The investigators were blinded of the clinical information.
Statistical analysis SAS 9.4 and Enterprise Guide 6.1 programs (SAS Institute, Inc., Cary, NC) were used for statistical analyses. Variations in EGFR GCN between different patient subgroups in the RAS wt population were tested with the Mann-Whitney U test (nonparametric one-way ANOVA). v 2 test or Fisher's exact test were used for frequency table data analyses. Univariate survival analysis was performed with Kaplan-Meier, log-rank test and Cox proportional hazards regression model. Multivariate survival analysis was carried out by using Cox's proportional hazards regression model. All statistical tests were two-sided. p-Values <0.05 were considered statistically significant. PFS was calculated from the onset of anti-EGFR treatment until disease progression. OS was calculated from the onset of anti-EGFR therapy until death of any cause.
Results
RAS, BRAF and PIK3CA gene mutation frequencies RAS, BRAF and PIK3CA gene mutation analysis was successful on 86.3% of the patients (88/102). The testing could not be performed due to technical reasons in 4.9% (5/102) of the cases and in nine cases (8.8%) the tumour specimen had run out or was for other reasons not available. Therefore, the patient material suitable for our study with both EGFR SISH and RAS, BRAF, as well as PIK3CA gene mutation analysis tests performed included altogether 88 patients. Additional RAS mutations were found in 28.4% of the initially KRAS exon 2 wt patients. The majority of the RAS mutations were found in the KRAS gene. 47.7% (42/88) of the patients were RAS/BRAF/PIK3CA wild-type. The RAS, BRAF and PIK3CA gene mutation analysis results are shown in Table 2 . Mutations in multiple genes were found in 11 tumours. A mutation in one single PIK3CA exon was a rare event, since PIK3CA mutations were in 85.7% (12/14) of the cases found together with other mutations. The tumours with multiple mutations are presented in supplementary  Table S1 .
EGFR GCN in the RAS wt patient cohort
The mean EGFR GCN was 4.5, median 5.0 (range, 2.4-10). The EGFR GCN was 4.0 in 59.1% (52/88) of the entire cohort and 63.5% of the RAS wt patients (40/63). EGFR GCN was statistically higher in left-sided tumours than in right-sided tumours (Kruskal-Wallis test, p 5 0.005). Seventy-five percent (33/
The majority of the RAS wt patients in our study had died of metastatic CRC during the follow-up period. The median follow-up time of the RAS wt patients was 12.4 months (range 3.3-58.5 months). At the end of the follow-up period 7/63 (11.1%) RAS wt patients were alive. All these patients had undergone liver resection and of these patients 4/7 had remained disease-free. EGFR GCN was not associated with follow-up status of the patients.
EGFR GCN and response to anti-EGFR therapy
The majority (93%, 28/30) of RAS/BRAF/PIK3CA wt patients with an EGFR GCN 4.0 experienced clinical benefit from anti-EGFR therapy [partial response (PR) or stable disease (SD)], in comparison to 50% of the patients with an EGFR GCN <4.0. Similarly, the majority (85%, 34/40) of the RAS wt patients with an EGFR GCN 4.0 benefitted from anti-EGFR therapy [SD, PR or complete response (CR)]. In contrast, less than half of the patients with an EGFR GCN <4.0 (43.5%, 10/23) showed clinical benefit (v 2 test, p 5 0.005). A similar finding was observed in the chemorefractory patients treated with anti-EGFR therapy in third line or more (n 5 36). Eighty-eight percent of the chemorefractory patients with an EGFR GCN 4 benefitted from the monoclonal antibody treatment. Treatment response to cetuximab or panitumumab was not associated with EGFR GCN in the BRAF mutant (n 5 20) or RAS mutant (n 5 25) patient cohorts. The results are presented in Table 3 .
A high EGFR GCN is associated with improved PFS in RAS wt metastatic CRC both in univariate and multivariate survival analysis A high EGFR GCN (4.0) associated with improved PFS in all wt patient cohorts tested. In RAS mutant and BRAF mutant patients no such association was observed. On the other hand, patients with RAS/BRAF/PIK3CA wt, EGFR GCN <4.0 tumours did not obtain any survival benefit as compared to patients with mutation in any of the pathway genes. KaplanMeier survival curves are presented in Figure 1 . 
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The following characteristics were, in addition to an elevated EGFR GCN, associated with improved PFS: left-sided location of primary tumour (Log-rank, p <0.0001), welldifferentiated tumour (Log-rank, p 5 0.03) and BRAF wt tumour (Log-rank, p <0.0001). Gender, age, type of anti-EGFR therapy (cetuximab vs. panitumumab), or PIK3CA gene mutation status did not associate with PFS.
The variables that significantly associated with PFS in univariate analysis were included in the Cox's multivariate analysis model. The variables included were: EGFR GCN, leftvs. right-sided location of primary tumour, BRAF mutation status and tumour differentiation grade. The only statistically significant independent predictor of PFS was EGFR GCN A high EGFR GCN is associated with improved OS in chemorefractory metastatic CRC Despite a clear difference in median OS time (10.3 vs. 17 months) according to EGFR GCN status (<4.0 vs. 4.0) in the RAS wt patient cohort, a statistically significant difference in OS was not observed. On the other hand, EGFR GCN predicted both PFS and OS in the RAS wt patients with chemorefractory disease. The results are presented in Table 3 and Kaplan-Meier survival curves shown in Figure 2 .
Left-sided location of primary tumour (Log-rank, p 5 0.002), well-differentiated tumour grade (Log-rank, p 5 0.005) and BRAF wt status of the primary tumour (Logrank, p 5 0.01) were additional factors associated with favourable OS in RAS wt disease (n 5 63) as well as in chemorefractory RAS wt patients (left-sided location of primary tumour, p 5 0.003; well-differentiated tumours, p 5 0.001; BRAF wt primary tumour, p 5 0.01). Gender, age at diagnosis, PIK3CA mutation status of primary tumour, or type of anti-EGFR monoclonal antibody therapy did not associate with OS.
The variables that were significantly associated with OS in univariate analysis of the chemorefractory RAS wt patients (EGFR GCN, left-vs. right-sided primary tumour location, BRAF status, tumour differentiation grade) were included in the Cox's proportional hazards regression model. None of the variables were found to independently predict OS in the chemorefractory phase of the disease.
Discussion
Improved methods are needed to stratify metastatic CRC patients benefitting from anti-EGFR treatment. Here, we Figure 1 . Progression free survival of metastatic colorectal cancer patients treated with cetuximab or panitumumab 6 cytotoxic therapy stratified by RAS, BRAF and PIK3CA mutation status and EGFR gene copy number. Progression free survival of RAS/BRAF/PIK3CA wild type patients or patients with a mutation in either one of these three genes. RAS/BRAF/PIK3CA wild type EGFR GCN 4.0 patients show significant survival benefit over the other groups. show that EGFR GCN serves as a strong predictive marker for RAS wt, BRAF wt and RAS/BRAF/PIK3CA wt metastatic CRC patients treated with cetuximab or panitumumab 6 cytotoxic therapy. EGFR GCN does not work as a predictive marker in the patients with mutated RAS or BRAF tumours. Importantly, the response to RAS/BRAF/PIK3CA wt, EGFR GCN <4.0 tumours does not differ from tumours with a mutation in the pathway genes.
Our KRAS and NRAS gene mutation analysis with the NGS technique yielded an additional gene mutation frequency of 28% in the patients initially diagnosed as KRAS exon 2 wt with the DxS KRAS mutation kit. Interestingly, seven of the new mutations were found in KRAS exon 2. No NRAS exon 4 mutations were observed, which is in line with previously reported mutation frequencies. 3 The 22.7% BRAF mutation incidence found in our study is higher than the 5-12% mutation frequency reported in most previous studies, but similar to the 21% rate reported in a prospectively collected, unselected Scandinavian metastatic CRC patient cohort of 798 patients by Sorbye et al.
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The majority (63.5%) of the primary tumours in the RAS wt patient population of our study had an EGFR GCN 4.0. Eighty-five percent of the RAS wt patients with an EGFR GCN 4.0 showed clinical benefit (CR 1 PR 1 SD) from anti-EGFR therapy in comparison to 43.5% of the patients with an EGFR GCN <4.0. The proportion of benefitting RAS wt patients is somewhat higher than that of KRAS wt patients in our previous reports where clinical benefit rate was 73-78% as well as our study with a benefit rate of 79%.
Our results show that left-sided location of the primary tumour in the gut is associated with both improved PFS and OS, which is in line with previous studies. 14, 15 Elevated EGFR GCN was more common in left-sided than in right-sided tumours in our study as supported by the findings of Missiaglia et al. who reported that EGFR and HER2 amplifications are more frequently observed in distal than proximal CRC tumours. 16 Left-and right-sided tumours differ molecularly from each other also regarding, e.g. BRAF mutations, which are associated with poor prognosis in metastatic CRC and more common in right-sided tumours than in left-sided tumours. [14] [15] [16] One could speculate that the association between a high EGFR GCN and improved disease outcome observed in our study is in fact due to these factors. However, when we included BRAF status, tumour differentiation grade, EGFR GCN and primary tumour location in multivariate survival analysis EGFR GCN was the only factor that independently predicted PFS. Therefore, our results indicate that EGFR GCN has indeed an independent predictive role in metastatic CRC patients treated with anti-EGFR therapy.
When including only the patients treated with anti-EGFR 6 cytotoxic therapy in third line (chemorefractory phase of the disease), a statistically significant difference in OS was observed, 12.4 vs. 7.3 months. However, in multivariate survival analysis EGFR GCN did not prove to be an independent predictor of OS in the chemorefractory patient subgroup. This might be due to the small number of patients in this subcategory of patients.
When analysing the RAS wt patient cohort of our study, a high EGFR GCN (4.0) did not statistically significantly associate with improved OS despite a clear difference in OS time (17.0 vs. 11.3 months), which differs from the findings in our two previous studies where both PFS and OS were positively associated with a high EGFR GCN in KRAS wt patients. 10, 11 The explanation for the lack of a statistically significant prolongation of OS might at least in part be explained by the retrospective nature of our study where the treatment protocol is not standardised and therefore inevitable variation is seen both in the timing of anti-EGFR therapy (early vs. late lines) and in subsequent therapies administered after anti-EGFR 6 cytotoxic therapy.
In a recent study Llovet et al. studied the predictive value of EGFR pathway genes, including EGFR GCN analysed by fluorescent in situ hybridisation (FISH), in metastatic CRC patients treated with anti-EGFR 1 chemotherapy in first line and found no statistically significant association between EGFR GCN and ORR, PFS or OS even though patients with EGFR amplification responded better to anti-EGFR therapy and had a longer survival than EGFR amplification negative patients. 17 Of note, EGFR GCN could not be evaluated in 30.5% (32/105) of the cases and EGFR amplification was diagnosed in only 16.7% (12/72) of the KRAS wt patients with evaluable EGFR GCN included in their study. In comparison, 63.5% (40/63) of the patients included in our study were found to have an EGFR GCN 4.0. These differences highlight the need for standardised methods for EGFR GCN analysis. EGFR GCN detection by SISH has several advantages in comparison to FISH analysis. SISH results are analysed by conventional bright field light microscopy and can therefore be easily performed. In addition, the chromogen of SISH is very stable in contrast to the fluorochromes utilised in FISH. Morphological identification of the tissue is superior with the SISH technique in comparison to FISH. This is especially important when assessing EGFR GCN from areas with highest EGFR protein expression, which requires accurate interpretation of the tissue anatomy. Finally, SISH is a fully automated technique in contrast to FISH which is manually performed.
A meta-analysis on this subject concludes that the utility of EGFR GCN as a predictive biomarker is at the moment limited by the lack of a standardised, reproducible method for EGFR GCN detection. 18 Our method, which takes into account the heterogeneity of EGFR GCN within tumours by combining IHC and a fully automated SISH technique improves reproducibility and enables morphological identification of the tissues.
The mechanism, by which EGFR GCN is linked with favourable response to anti-EGFR therapy remains to be solved. Interestingly, we only very rarely detect a true EGFR amplification, but typically EGFR GCN increase is associated with Chr 7 polysomy. 10 Thus, the situation is different from the true EGFR amplification detected with the same technique in glioblastomas or in gastric cancer. 19 In future studies, it would be interesting to compare the predictive value of our SISH based technique to other techniques, such as digital droplet (dd)PCR, successfully used to detect HER2 amplification. 20 In conclusion, our results indicate that EGFR GCN serves as a promising predictive marker also in the RAS wt metastatic CRC patient population treated with anti-EGFR therapy similar to our previous results in KRAS exon 2 wt patients. Interestingly EGFR GCN seems to add predictive value also in the RAS/BRAF/PIK3CA wt patients. However, the retrospective nature of our study, the small patient number, as well as the heterogeneity of the treatment lines are limitations of our study that need to be taken into account when interpreting the results. Further validation studies, carried out in a prospective manner are ongoing to confirm our results.
